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A B S T R A C T
Introduction: Danon disease is an extremely rare X-linked dominant disorder characterized by
progressive cardiomyopathy, muscle weakness, and mild mental retardation. Most cases harbor
nonsense, frameshift, or splice-site mutations in LAMP2 that result in lysosome-associated membrane
protein-2 (LAMP-2) deﬁciency and lysosomal defects. The identiﬁcation of LAMP2 mutations makes it
possible to detect female carriers with signiﬁcant cardiomyopathy. Therefore, it is of paramount
importance to develop useful carrier detection methods.
Methods: To screen for diminished LAMP-2 expression among female patients with progressive
cardiomyopathy, we developed a ﬂow cytometric method to detect LAMP-2-deﬁcient leukocytes.
Results: In healthy controls, all circulating leukocyte populations, including granulocytes, monocytes,
and lymphocytes, expressed signiﬁcant levels of LAMP-2. In contrast, cells from a male patient with
Danon disease lacked detectable LAMP-2. His younger twin sisters showed reduced levels of LAMP-2
expression with characteristic bimodal ﬂuorescence intensity patterns. The percentage of LAMP-2-
negative cells in the asymptomatic sibling was nearly the same as that in the symptomatic sibling.
Conclusion: We developed a ﬂow cytometric assay for LAMP-2 expression that can serve as a rapid
primary screening method to detect carriers of LAMP-2 deﬁciencies. This assay will narrow the target
population before subjecting patients to more laborious and expensive gene mutation analysis.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Danon disease, an X-linked cardioskeletal myopathy, was
originally reported as ‘‘lysosomal glycogen storage disease with
normal acid maltase’’ by Danon et al. in 1981 [1]. The ﬁrst two cases
were unrelated young boys, and muscle biopsy led to the diagnosis
of characteristic vacuolar myopathy in each case. In 2000, Nishino
et al. reported that mutations in LAMP2, which resides on
chromosome Xq24 and encodes the lysosome-associated mem-
brane protein-2 (LAMP-2), are responsible for the primary defect in
Danon disease [2]. LAMP-2, ﬁrst identiﬁed in 1983, is a lysosomal
membrane glycoprotein. It is critical for the process of autophagy,
which involves lysosomal fusion to the autophagosome, maturation
of autophagic vacuoles, and chaperon-mediated protein transport to* Corresponding author at: Department of Pediatrics, School of Medicine,
Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University,
13-1 Takaramachi, Kanazawa 920-8641, Japan. Tel.: +81 76 265 2313;
fax: +81 76 262 1866.
E-mail address: kohta@staff.kanazawa-u.ac.jp (K. Ohta).
http://dx.doi.org/10.1016/j.jjcc.2014.09.011
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightslysosomes. Autophagy is a cytoprotective pathway that eukaryotic
cells use to degrade and recycle cytoplasmic contents and prevent
starvation [3]. Under normal conditions, autophagy represents an
important homeostatic mechanism for the maintenance of normal
cardiovascular function and morphology [4]. Impaired autophagy
leads to cardiac hypertrophy in LAMP-2-deﬁcient mice [5].
Danon disease, which is clinically characterized by the triad of
cardiomyopathy, skeletal myopathy, and mental retardation,
exhibits a large spectrum of clinical characteristics. Dilated
cardiomyopathy can coexist with hypertrophic cardiomyopathy
within a family whose members have Danon disease. The clinical
presentation of Danon disease is always more severe in males than in
females because of its X-linked dominance [6]. In male patients, the
clinical course is progressive and may lead to premature death from
arrhythmia or severe heart failure by the end of the second or third
decade of life. In affected females, the disorder sets in later than it
does in males and predominantly involves the cardiac muscle.
However, the cardiac phenotype can be severe even in some females
[7,8]. Even among female patients, heart transplantation is the only
effective treatment for advanced heart failure [9,10]. reserved.
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reported [11]. Her family members were all healthy and did not
show any laboratory abnormalities. The patient herself had a de
novo mutation in LAMP2. Other family cases indicative of germline
mutations have been reported [12]. Therefore, the absence of
familial history should not exclude a diagnosis of Danon disease.
Two studies strongly suggest that Danon disease occurs more
frequently than has been reported. Arad et al. detected LAMP2
mutations in 2 of 35 patients with hypertrophic cardiomyopathy
[13]. Yang et al. identiﬁed LAMP2 nonsense mutations in 2 of
50 pediatric hypertrophic cardiomyopathy cases [14]. Therefore, a
diagnosis of Danon disease should be considered whenever a
patient with unexplained ventricular hypertrophy is encountered.
The ability to diagnose Danon disease during its earliest stages
is key to determine the most appropriate therapeutic intervention,Fig. 1. Images of patients. (A) Chest X-ray. Enlargement of a central shadow is observed
imaging. Images of DD1 show marked hypertrophy of the left ventricular wall and la
hypertrophy than DD1 and no late gadolinium enhancement. Neither hypertrophy nor 
resting 12-lead electrocardiogram (ECG). ECG of DD1 shows prominent voltage and a gia
abnormalities. (D) Full resting 12-lead ECG of DD1.preventing sudden cardiac death, and improving patient prognosis.
Broad diagnostic screening using a simple and easy method is
necessary to diagnose more patients. Assaying LAMP-2 expression
in the peripheral leukocytes of patients with Danon disease is
minimally invasive and beneﬁcial [15–17], but this method has not
yet been adapted as a screening test for asymptomatic patients.
In the present study, we describe a family with Danon disease
that has no apparent inheritance. We employed immunohisto-
chemical and ﬂow cytometric analysis to detect LAMP-2 expres-
sion in the peripheral leukocytes of all family members and
identiﬁed two preclinical heterozygous females (preclinical
female carriers). To the best of our knowledge, this is the ﬁrst
report of ﬂuorescence-activated cell sorting (FACS) detection of
LAMP-2-negative leukocytes being used to screen for Danon
disease in females. FACS analysis of leukocytes can contribute to in DD1. (B) A short-axis view of gadolinium-enhanced cardiac magnetic resonance
te gadolinium enhancement below the epithelium. Images of DD2 show milder
late gadolinium enhancement was observed on images of DD3. (C) V5-lead from a
nt negative T wave, whereas that of DD2 shows a short PR interval. DD3 has no ECG
Table 1
Clinical ﬁndings of patients. LVPWD, left ventricular end diastolic posterior wall dimension; IVSD, interventricular septal end diastolic dimension; ECG, electrocardiography;
SVT, supraventricular tachycardia; WPW syndrome, Wolff–Parkinson–White syndrome; AVB, atrioventricular block; CK, creatine kinase; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; LDH, lactate dehydrogenase; BNP, brain natriuretic peptide.
DD1 (III-4) DD2 (III-5) DD3 (III-6) Control (n = 8)
Sex Male Female Female 4 males/4 females
Subjective symptom General fatigue Palpitation None None
Age at diagnosis 14 years 11 years 11 years 10–14 years
Diastolic LVPWD (mm) 25.8 12.1 6.9 7.0  0.3
Diastolic IVSD (mm) 21.7 10.8 7.0 6.7  0.4
ECG abnormality Giant negative T wave SVT WPW syndrome AVB(II) None None
Muscle weakness Upper extremities None None None
Mental retardation None None None None
CK (IU/l) 567 156 125 134  47
AST (IU/l) 185 67 19 24  5
ALT (IU/l) 150 27 13 12  4
LDH (IU/l) 924 516 179 199  25
BNP (pg/ml) 439.5 22.6 12.2 4.9  4
Fig. 2. Pedigree of DD1. III-4 (DD1) is the proband and III-5 (DD2) and III-6 (DD3) are
monozygotic twins. DD2 is a symptomatic female, and DD3 is an asymptomatic
female carrier.
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but also in heterozygous females.
Materials and methods
Study subjects
A 13-year-old Japanese boy (proband DD1) was referred to our
hospital in September 2008 with chronic jaundice and elevated
liver enzyme levels. Three years earlier, elevated levels of
transaminases [serum aspartate aminotransferase (AST)/alanine
aminotransferase (ALT)] and creatine kinase (CK) had been
incidentally detected during routine examinations. The enzyme
levels did not return to normal; in fact, they had increased by July
2008. Physical examination revealed muscle weakness in the
upper extremities and mild mental retardation. A systolic ejection
murmur was heard at the second left interspace; therefore, we
performed cardiac investigations. His chest X-ray revealed mild
cardiomegaly (Fig. 1A), whereas ultrasound cardiography (UCG)
revealed marked hypertrophy in his ventricular septum and left
ventricular wall without outﬂow obstruction. The end-diastolic
left ventricular dimension was 29.1 mm. Systolic and diastolic
functions were almost normal. Magnetic resonance imaging (MRI)
also revealed cardiac hypertrophy with late gadolinium enhance-
ment (Fig. 1B). Electrocardiography (ECG) demonstrated distinct
giant negative T waves in leads V3–6 and prominent voltages
(Fig. 1C and D). Danon disease was suspected because of the
following characteristic symptoms: unexplained left ventricular
hypertrophy with a giant negative T wave, elevated CK and
transaminase levels, and muscle weakness in the upper extremi-
ties (Table 1).
The family pedigree of DD1 is shown in Fig. 2. No parental
consanguinity was present. To the best of our knowledge, no other
family members showed symptoms of Danon disease at the time of
initial DD1 presentation. To determine penetrance, we evaluated
the parents, sisters, and the maternal uncle of DD1. We also
investigated 8 healthy individuals (4 males and 4 females) with no
signs of speciﬁc cardiac or systemic disorders, as controls.
The Human Research Committee of Kanazawa University
Graduate School of Medical Science approved this study
(No. 119), and informed consent was obtained from subjects
according to the Declaration of Helsinki.
Cardiac function and laboratory data
All patients and controls underwent physical examinations,
chest radiography, ECG, and UCG. Left ventricular size and function
were evaluated by M-mode and 2-dimensional Doppler and colorDoppler imaging. Some patients were subjected to MRI studies.
Serum levels of transaminases (AST/ALT), lactate dehydrogenase
(LDH), CK, and brain natriuretic peptide were also determined.
Genetic analysis
Genomic DNA was extracted from whole blood using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Primers were
designed to amplify all coding exons of LAMP2, including adjacent
exon–intron boundaries [2]. Polymerase chain reaction (PCR)
fragments were puriﬁed using the QIAquick PCR puriﬁcation kit
(Qiagen). Sequences were determined in the forward and reverse
directions using BigDye1 Terminator v3.1 and v1.1 cycle
sequencing kits (Applied Biosystems, Foster City, CA, USA).
Immunohistological detection of LAMP-2
Peripheral blood mononuclear cells (PBMCs) were isolated from
patients and normal controls by Ficoll–Hypaque gradient centri-
fugation. Slides with PBMC cytospin preparations were air dried
and ﬁxed in cold acetone. LAMP-2 expression was examined by
immunohistochemistry using an anti-LAMP-2 antibody (BD
Biosciences PharmingenTM, Tokyo, Japan).
Flow cytometric analysis of leukocytes
Whole blood was used to simplify the screening method. After
incubation with lysis buffer, intracellular staining with monoclonal
antibodies was performed according to standard procedures. In
brief, 1  106 leukocytes were incubated with 100 ml of Fix
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solution; BD Biosciences Pharmingen) for 20 min at room
temperature. After two washes with this solution, the cells were
resuspended in 100 ml of permeabilization solution, and 4 ml of a
primary monoclonal antibody directed against LAMP-1/LAMP-2
(BD Biosciences Pharmingen) or isotype-matched monoclonal
antibodies (BD Biosciences Pharmingen) were added. LAMP-1 and
LAMP-2 are homologous lysosomal membrane proteins encoded
by distinct genes (LAMP1 is located on 13q34) [18]. LAMP-1 was
used as a control for the integrity of the preparation. After
incubation for 20 min, cells were washed twice in the permeabi-
lization solution, resuspended in 200 ml of phosphate-buffered
saline, and analyzed on the FACS Calibur ﬂow cytometer
supported by cellquest software (Beckton Dickinson, San Diego,
CA, USA).
Sensitivity of ﬂow cytometric analysis for detecting LAMP-2 in
leukocytes
We mixed varying numbers of granulocytes obtained from a
healthy male control and DD1 and determined the percentage of
LAMP-2-negative cells by ﬂow cytometry. Intracellular staining
was performed as described above.
Results
Clinical characterization of female carriers
The sisters of DD1 (DD2 and DD3) were monozygotic twins. One
developed mild cardiomyopathy, whereas the other did not. No
abnormalities were observed in DD2 during her school medical
check-up (which included ECG) at the age of 6. She was 11 years old
when we examined her. Although she did not exhibit any obvious
symptoms of cardiac disease, mild left ventricular hypertrophy
was observed by UCG. No late gadolinium enhancement was
observed on MRI (Fig. 1B). Her ECG demonstrated intermittent
Wolff–Parkinson–White syndrome (Fig. 1C) and grade 2 atrioven-
tricular block. Her AST and LDH levels were slightly elevated
(Table 1), and she did not exhibit skeletal myopathy or mentalFig. 3. Mutation detection in the family. Deletion of GTGA at the 30 end of exon 6 is
(heterozygous) but not in that of the parents (II-3 and II-4).retardation, thus making her family history of Danon disease the
only clue to an accurate diagnosis.
DD3 was screened simultaneously with DD2. She also did not
exhibit deﬁnitive symptoms. Compared with DD2, her chest X-ray,
UCG, MRI, and ECG results were normal (Fig. 1). Transaminase
levels were not elevated and no muscle weakness was detected
(Table 1). The parents of DD1 exhibited no overt clinical symptoms.
No abnormalities were identiﬁed in their ECG, UCG, or blood
enzyme levels. The ECG and UCG ﬁndings of DD1’s maternal uncle
were also normal.
Molecular characterization
No LAMP2 mutations were detected in DD1’s parents (II-4 and
II-3). In contrast, we identiﬁed a 4-bp deletion in LAMP2 at the
intron 6 splice site (IVS6+1_4delGTGA) in DD1 (Fig. 3). DD2 and
DD3 were found to be heterozygotes with one copy each of the
wild type (upper sequence) and IVS6+1_4delGTGA (lower se-
quence) sequences. LAMP2 mutations were not detected in any of
the control samples.
Immunohistochemistry
Representative LAMP-2 expression proﬁles in PBMCs are shown
in Fig. 4. All control monocytes (open arrow heads) and a signiﬁcant
portion of the control lymphocytes expressed LAMP-2. Some
lymphocytes had less cytoplasm, making it difﬁcult to judge the
intracellular LAMP-2 expression microscopically. Therefore, we
analyzed LAMP-2 expression in monocytes. DD1’s monocytes lacked
detectable LAMP-2 immunoreactivity (arrows). The heterozygote
females (DD2 and DD3) possessed both LAMP-2-positive (open
arrow heads) and LAMP-2-negative monocytes (arrows). This
chimerism was conﬁrmed by FACS.
FACS analysis of leukocytes
We ﬁrst quantiﬁed intracellular LAMP-2 expression in each
leukocyte subpopulation obtained from the peripheral blood
samples of normal controls (Fig. 5). LAMP-2 was expressed in all demonstrated in the genomic DNA of DD1 (hemizygous) and of DD2 and DD3
Fig. 4. Immunoreactivity in peripheral blood mononuclear cells. The control shows
lysosome-associated membrane protein-2 (LAMP-2) expression in all peripheral
blood mononuclear cells. DD1 has no detectable LAMP-2 expression, and both DD2
and DD3 show chimerism, i.e. LAMP-2-positive and LAMP-2-negative cells. ~,
LAMP-2-positive monocyte; !, LAMP-2-negative monocyte.
Fig. 6. Quantitative analysis of lysosome-associated membrane protein-2
(LAMP-2)-negative cells. (A) Actual percentages of LAMP-2-negative cells are
shown on left side of each panel, and measured percentages are shown in each
panel. (B) Measured percentages of LAMP-2-negative cells are consistent with
actual percentages. FITC, ﬂuorescein isothiocyanate; FCM, ﬂow cytometry.
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monocytes, and CD56+ NK cells than in CD20+, CD4+, or CD8+
lymphocytes. Monocytes expressed LAMP-2 as intensely as
granulocytes. Because large leukocytes could have been included
in the monocyte region of the plot, we chose to use granulocytes for
patient analysis and gated the granulocyte region.
An investigation of the sensitivity of the FACS data showed
that we could detect very small percentages (0.78%) of LAMP-
2-negative cells precisely (Fig. 6).Fig. 5. Intracellular lysosome-associated membrane protein-2 (LAMP-2) expression
in leukocyte subpopulations. LAMP-2 expression is more intense in granulocytes
(Gr), monocytes (Mono), and CD56+ NK cells (CD56+) than in lymphocytes (CD4+,
CD8+, and CD20+). FITC, ﬂuorescein isothiocyanate.Healthy controls showed a single LAMP-1-positive peak and a
single LAMP-2-positive peak (Fig. 7). Only representative data are
shown in Fig. 7. Approximately 99.5–99.9% (mean 99.7%) of the
cells in healthy control samples were LAMP-2 positive. DD1Fig. 7. LAMP-1 and LAMP-2 expressions by granulocytes. DD1 has no detectable
LAMP-2 expression but expresses normal LAMP-1 levels. DD2 and DD3 show two
peaks of LAMP-2 expression. The lower peak is of the same intensity as that for DD1.
Therefore, this peak can be attributed to LAMP-2-negative cells. The higher peak
shows the same LAMP-2 signal intensity as that shown by healthy controls. These
data indicate that granulocytes of female patients contain LAMP-2-negative and
LAMP-2-positive cells. The ratio of LAMP-2-positive to LAMP-2-negative cells
exhibited by DD2 is similar to that displayed by DD3. LAMP, lysosome-associated
membrane protein; FITC, ﬂuorescein isothiocyanate.
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peak, indicating a deﬁcit of LAMP-2 in all of DD1’s leukocyte
subpopulations. In contrast, the LAMP-1-positive peak displayed
the same intensity as that in the healthy controls.
The two heterozygous females (DD2 and DD3) showed identical
patterns of double peaks. The ﬂuorescence intensities of their
LAMP-2-negative peaks were the same as those for DD1, indicating
a deﬁcit in LAMP-2 expression in these cells. The intensities of their
LAMP-2-positive peaks, however, were the same as those of the
healthy controls, indicating normal LAMP-2 expression in these
cells. Although DD3 was asymptomatic, the percentage of her
LAMP-2-negative cells was similar to that in symptomatic DD2. To
prove that the LAMP-2 negative cells contained no lymphocytes,
we puriﬁed the granulocytes by Ficoll–Hypaque gradient centri-
fugation and analyzed them by the same FACS method. The double
peaks reappeared, revealing that the granulocytes of the female
patients consisted of either LAMP-2-positive or LAMP-2-negative
cells. In summary, a single LAMP-2-negative peak in male patients
(no LAMP-2 expression) and double peaks in female patients
characterized Danon disease.
Discussion
Since 2000, Danon disease has been diagnosed by PCR-based
mutation detection technologies and Western blot analysis of
LAMP-2 expression. Almost all reported LAMP2 mutations lead to
LAMP-2 protein loss through frameshift or nonsense mutation.
However, in 2010, Yang discovered LAMP2 microdeletions in
patients with Danon disease [19]. In these cases, LAMP-2 was
undetectable, but short range PCR-based mutation detection
technologies missed these patients, providing a compelling
argument for employing both genetic and protein expression
analyses to diagnose Danon disease.
Here we describe the development of a ﬂow cytometric assay
that greatly facilitates the detection of females heterozygous for
Danon disease. The assay is based on the detection of the lysosomal
protein LAMP-2 in peripheral blood leukocytes. In normal controls,
all circulating leukocyte populations, including granulocytes,
monocytes, and lymphocytes, expressed signiﬁcant levels of
LAMP-2. This assay can be used for any patient with or without
symptoms of Danon disease; it takes less time and is less expensive
than genetic analysis. Accordingly, it is more suitable as an initial
screening process.
Males have one copy of the X chromosome; thus, all cells from
male patients with Danon disease lacked detectable LAMP-2. A
potential imbalance of gene expression from the two X chromo-
somes in females is resolved by inactivating one X chromosome.
X-chromosome inactivation is a stochastic event that occurs
during the early stages of embryonic development. In each cell, a
choice is made independently. Therefore, there are two possible
patterns of LAMP-2 expression in female patients with Danon
disease: positive expression by normal paternal X chromosomes
and negative expression by affected maternal X chromosomes.
Primary immunodeﬁciency diseases such as X-linked agam-
maglobulinemia and Wiskott–Aldrich syndrome are diagnosed by
protein expression analysis using FACS. In these X-linked inherited
diseases, heterozygous females usually do not exhibit clinical
symptoms, with the exception of some rare cases. Protein levels in
the tissues of affected females can be reduced because of skewed
X-chromosome inactivation. Fanin et al. reported an X-chromo-
some inactivation analysis in three female patients of Danon
disease and found a random pattern of inactivation in leukocytes.
The mean skewing rate in blood leukocytes was 60% [17].
We believe that our analysis can demonstrate chimerism,
even if some female patients with Danon disease show small
percentages of LAMP-2-negative cells by skewed X-chromosomeinactivation, because we could detect as few as 0.8% of cells lacking
LAMP-2 (Fig. 6). The sensitivity of ﬂow cytometric assay, which can
detect the ﬂuorescent intensity of each cell, is much higher than
that of Western blot analysis. On the other hand, LAMP-2 is
expressed in all leukocytes in healthy males and females;
therefore, LAMP-2-negative cells could not be detected by ﬂow
cytometric assay. This indicates that both the sensitivity and
speciﬁcity of this assay are extremely high. Nevertheless,
conﬁrmation by genetic analysis is necessary.
We used our assay to detect LAMP-2 expression in a family that
has a male member who suffers from Danon disease. There was no
apparent inheritance, although we were able to identify two young
heterozygous females (DD2 and DD3) without the clinical onset of
Danon disease. The clinical courses of DD2 and DD3 should prove
to be highly informative about the early stages of Danon disease.
DD2 and DD3 are monozygotic twins with identical leukocyte
LAMP-2 expression and LAMP2 mutations; DD2 was symptomatic,
whereas DD3 was asymptomatic. In addition, there were no
differences in their lifestyles. We were therefore unable to account
for the differences in their clinical ﬁndings. Using our ﬂow
cytometric assay, we can investigate LAMP-2 expression not only
in leukocytes but also other cells and tissues. Such a study could
explain the complex organ-speciﬁc symptoms and different
severity among patients with Danon disease.
Inherited cardiomyopathies are genetically heterogeneous
[20]. A majority of childhood-onset isolated cardiac hypertrophies
are caused by genetic mutations for which adults are routinely
screened [21,22]. However, in some young patients, nonsarcomeric
causes such as inborn errors of metabolism, mitochondrial
dysfunction, and neuromuscular conditions have been increasing-
ly recognized [23], and the outcomes depend largely on the cause
[24]. Among all causes of ventricular hypertrophy, the clinical
course of Danon disease is the most aggressive. Early diagnosis of
Danon disease should be highly informative of prognosis, and this
disease should always be ruled out in patients presenting with
unexplained cardiomyopathy.
Our present study demonstrates that ﬂow cytometric analysis
of LAMP-2 expression by leukocytes provides a novel, rapid,
simple, and highly sensitive screening method for the early
detection of Danon disease.
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